Literature DB >> 8471662

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera.

M Hino1, E Futami, S Okuno, T Miki, Y Nishizawa, H Morii.   

Abstract

A patient with polycythemia vera associated with chromosomal translocation (6;8) (q27;p11) and IgA monoclonal gammopathy was treated with interferon alpha-2b. Interferon alpha-2b induced good hematological control and reduced only IgA levels, but not IgG and IgM levels. In addition, cytogenetic improvement was obtained, the abnormal cells with chromosomal translocation declining from 100% to 50%. Interferon alpha may have selective effects on a malignant clone in polycythemia vera.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8471662     DOI： 10.1007/bf01697629

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  7 in total

1.  Recombinant interferon alpha in the treatment of polycythemia vera.

Authors:  E Cacciola; R Giustolisi; P Guglielmo; F Di Raimondo; E Cacciola; R D Calogero
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

2.  Alpha-interferon for polycythemia vera.

Authors:  S Ariad; W R Bezwoda
Journal:  Blood       Date:  1991-02-01       Impact factor: 22.113

3.  Recombinant interferon-alpha for treatment of polycythaemia vera.

Authors:  R T Silver
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

4.  A new treatment for polycythemia vera: recombinant interferon alfa.

Authors:  R T Silver
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

5.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

6.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.

Authors:  E S Kawasaki; S S Clark; M Y Coyne; S D Smith; R Champlin; O N Witte; F P McCormick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K McCredie; J M Trujillo; M J Keating; J U Gutterman
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245
  7 in total
  8 in total

1.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

2.  A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera.

Authors:  S Sacchi; P Leoni; M Liberati; A Riccardi; A Tabilio; P Tartoni; C Messora; A Vecchi; L Bensi; S Rupoli
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

Review 3.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

4.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Authors:  Alfonso Quintás-Cardama; Omar Abdel-Wahab; Taghi Manshouri; Outi Kilpivaara; Jorge Cortes; Anne-Laure Roupie; Su-Jiang Zhang; David Harris; Zeev Estrov; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Blood       Date:  2013-06-19       Impact factor: 22.113

5.  Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Authors:  Abdulraheem Yacoub; John Mascarenhas; Heidi Kosiorek; Josef T Prchal; Dmitry Berenzon; Maria R Baer; Ellen Ritchie; Richard T Silver; Craig Kessler; Elliott Winton; Maria Chiara Finazzi; Alessandro Rambaldi; Alessandro M Vannucchi; David Leibowitz; Damiano Rondelli; Murat O Arcasoy; Rosalind Catchatourian; Joseph Vadakara; Vittorio Rosti; Elizabeth Hexner; Marina Kremyanskaya; Lonette Sandy; Joseph Tripodi; Vesna Najfeld; Noushin Farnoud; Elli Papaemmanuil; Mohamed Salama; Rona Singer-Weinberg; Raajit Rampal; Judith D Goldberg; Tiziano Barbui; Ruben Mesa; Amylou C Dueck; Ronald Hoffman
Journal:  Blood       Date:  2019-10-31       Impact factor: 25.476

Review 6.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

7.  Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Authors:  Lucia Masarova; Keyur P Patel; Kate J Newberry; Jorge Cortes; Gautam Borthakur; Marina Konopleva; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek
Journal:  Lancet Haematol       Date:  2017-03-11       Impact factor: 18.959

Review 8.  Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.

Authors:  Joan How; Gabriela Hobbs
Journal:  Cancers (Basel)       Date:  2020-07-18       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.